Neurophth Therapeutics
About:
Neurophth is China's first gene therapy company for ophthalmic diseases.
Website: https://www.neurophth.com/
Top Investors: HongShan, Fosun International, BGI Group, Northern Light Venture Capital, Oriza Holdings
Description:
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Total Funding Amount:
$237M
Estimated Revenue Range:
$100M to $500M
Headquarters Location:
Wuhan, Hubei, China
Founded Date:
2016-07-01
Founders:
Dr Xiao Su, Li Bin
Number of Employees:
251-500
Last Funding Date:
2023-08-09
IPO Status:
Private
Industries:
© 2025 bioDAO.ai